LH
Labcorp's long game
Labcorp isn't just talking about next quarter's weather forecast. It's laying out a longer runway through 2029, with management expecting revenue to grow 5% to 8% annually, adjusted operating margins to widen by 75 to 150 basis points, and adjusted EPS to compound at 8.5% or more.
Why investors should care
That kind of outlook is basically corporate code for: "We think the business can keep grinding higher without needing a miracle." For a diagnostics and lab-testing company, steady compounding matters. You don't need a viral product launch when the pitch is consistent execution, better margins, and a few years of cash-flow muscle.
The fine print
Labcorp also reaffirmed its 2026 guidance, which tells the market the short-term script hasn't changed even while the company is looking way down the road. That's usually the kind of combo Wall Street likes: near-term stability plus a long-term growth story.
Big picture: Labcorp is trying to look less like a sleepy healthcare utility and more like a dependable compounder. Not flashy, but sometimes the tortoise with a spreadsheet wins the race.